These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

530 related articles for article (PubMed ID: 34428777)

  • 41. High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape.
    Schmidt F; Weisblum Y; Rutkowska M; Poston D; DaSilva J; Zhang F; Bednarski E; Cho A; Schaefer-Babajew DJ; Gaebler C; Caskey M; Nussenzweig MC; Hatziioannou T; Bieniasz PD
    Nature; 2021 Dec; 600(7889):512-516. PubMed ID: 34544114
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Reduced levels of convalescent neutralizing antibodies against SARS-CoV-2 B.1+L249S+E484K lineage.
    Álvarez-Díaz DA; Laiton-Donato K; Torres-García OA; Ruiz-Moreno HA; Franco-Muñoz C; Beltran MA; Mercado-Reyes M; Rueda MG; Muñoz AL
    Virus Res; 2022 Jan; 308():198629. PubMed ID: 34780883
    [TBL] [Abstract][Full Text] [Related]  

  • 43. SARS-CoV-2 Delta Variant Displays Moderate Resistance to Neutralizing Antibodies and Spike Protein Properties of Higher Soluble ACE2 Sensitivity, Enhanced Cleavage and Fusogenic Activity.
    Neerukonda SN; Vassell R; Lusvarghi S; Wang R; Echegaray F; Bentley L; Eakin AE; Erlandson KJ; Katzelnick LC; Weiss CD; Wang W
    Viruses; 2021 Dec; 13(12):. PubMed ID: 34960755
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes.
    Tada T; Dcosta BM; Samanovic MI; Herati RS; Cornelius A; Zhou H; Vaill A; Kazmierski W; Mulligan MJ; Landau NR
    mBio; 2021 Jun; 12(3):e0069621. PubMed ID: 34060334
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evolutionary and Phenotypic Characterization of Two Spike Mutations in European Lineage 20E of SARS-CoV-2.
    Ruiz-Rodriguez P; Francés-Gómez C; Chiner-Oms Á; López MG; Jiménez-Serrano S; Cancino-Muñoz I; Ruiz-Hueso P; Torres-Puente M; Bracho MA; D'Auria G; Martinez-Priego L; Guerreiro M; Montero-Alonso M; Gómez MD; Piñana JL; ; González-Candelas F; Comas I; Marina A; Geller R; Coscolla M
    mBio; 2021 Dec; 12(6):e0231521. PubMed ID: 34781748
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition.
    Kramer KJ; Johnson NV; Shiakolas AR; Suryadevara N; Periasamy S; Raju N; Williams JK; Wrapp D; Zost SJ; Walker LM; Wall SC; Holt CM; Hsieh CL; Sutton RE; Paulo A; Nargi RS; Davidson E; Doranz BJ; Crowe JE; Bukreyev A; Carnahan RH; McLellan JS; Georgiev IS
    Cell Rep; 2021 Oct; 37(1):109784. PubMed ID: 34592170
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa.
    Viana R; Moyo S; Amoako DG; Tegally H; Scheepers C; Althaus CL; Anyaneji UJ; Bester PA; Boni MF; Chand M; Choga WT; Colquhoun R; Davids M; Deforche K; Doolabh D; du Plessis L; Engelbrecht S; Everatt J; Giandhari J; Giovanetti M; Hardie D; Hill V; Hsiao NY; Iranzadeh A; Ismail A; Joseph C; Joseph R; Koopile L; Kosakovsky Pond SL; Kraemer MUG; Kuate-Lere L; Laguda-Akingba O; Lesetedi-Mafoko O; Lessells RJ; Lockman S; Lucaci AG; Maharaj A; Mahlangu B; Maponga T; Mahlakwane K; Makatini Z; Marais G; Maruapula D; Masupu K; Matshaba M; Mayaphi S; Mbhele N; Mbulawa MB; Mendes A; Mlisana K; Mnguni A; Mohale T; Moir M; Moruisi K; Mosepele M; Motsatsi G; Motswaledi MS; Mphoyakgosi T; Msomi N; Mwangi PN; Naidoo Y; Ntuli N; Nyaga M; Olubayo L; Pillay S; Radibe B; Ramphal Y; Ramphal U; San JE; Scott L; Shapiro R; Singh L; Smith-Lawrence P; Stevens W; Strydom A; Subramoney K; Tebeila N; Tshiabuila D; Tsui J; van Wyk S; Weaver S; Wibmer CK; Wilkinson E; Wolter N; Zarebski AE; Zuze B; Goedhals D; Preiser W; Treurnicht F; Venter M; Williamson C; Pybus OG; Bhiman J; Glass A; Martin DP; Rambaut A; Gaseitsiwe S; von Gottberg A; de Oliveira T
    Nature; 2022 Mar; 603(7902):679-686. PubMed ID: 35042229
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antibody cocktail effective against variants of SARS-CoV-2.
    Liang KH; Chiang PY; Ko SH; Chou YC; Lu RM; Lin HT; Chen WY; Lin YL; Tao MH; Jan JT; Wu HC
    J Biomed Sci; 2021 Nov; 28(1):80. PubMed ID: 34814920
    [TBL] [Abstract][Full Text] [Related]  

  • 49. RBD-mRNA vaccine induces broadly neutralizing antibodies against Omicron and multiple other variants and protects mice from SARS-CoV-2 challenge.
    Shi J; Zheng J; Zhang X; Tai W; Odle AE; Perlman S; Du L
    Transl Res; 2022 Oct; 248():11-21. PubMed ID: 35489692
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comprehensive mapping of binding hot spots of SARS-CoV-2 RBD-specific neutralizing antibodies for tracking immune escape variants.
    Yi C; Sun X; Lin Y; Gu C; Ding L; Lu X; Yang Z; Zhang Y; Ma L; Gu W; Qu A; Zhou X; Li X; Xu J; Ling Z; Xie Y; Lu H; Sun B
    Genome Med; 2021 Oct; 13(1):164. PubMed ID: 34649620
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant.
    Graham C; Seow J; Huettner I; Khan H; Kouphou N; Acors S; Winstone H; Pickering S; Galao RP; Dupont L; Lista MJ; Jimenez-Guardeño JM; Laing AG; Wu Y; Joseph M; Muir L; van Gils MJ; Ng WM; Duyvesteyn HME; Zhao Y; Bowden TA; Shankar-Hari M; Rosa A; Cherepanov P; McCoy LE; Hayday AC; Neil SJD; Malim MH; Doores KJ
    Immunity; 2021 Jun; 54(6):1276-1289.e6. PubMed ID: 33836142
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity.
    Lucas C; Vogels CBF; Yildirim I; Rothman JE; Lu P; Monteiro V; Gehlhausen JR; Campbell M; Silva J; Tabachnikova A; Peña-Hernandez MA; Muenker MC; Breban MI; Fauver JR; Mohanty S; Huang J; ; Shaw AC; Ko AI; Omer SB; Grubaugh ND; Iwasaki A
    Nature; 2021 Dec; 600(7889):523-529. PubMed ID: 34634791
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Global Prevalence of Adaptive and Prolonged Infections' Mutations in the Receptor-Binding Domain of the SARS-CoV-2 Spike Protein.
    Lennerstrand J; Palanisamy N
    Viruses; 2021 Sep; 13(10):. PubMed ID: 34696404
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19.
    Kaku Y; Kuwata T; Zahid HM; Hashiguchi T; Noda T; Kuramoto N; Biswas S; Matsumoto K; Shimizu M; Kawanami Y; Shimura K; Onishi C; Muramoto Y; Suzuki T; Sasaki J; Nagasaki Y; Minami R; Motozono C; Toyoda M; Takahashi H; Kishi H; Fujii K; Tatsuke T; Ikeda T; Maeda Y; Ueno T; Koyanagi Y; Iwagoe H; Matsushita S
    Cell Rep; 2021 Jul; 36(2):109385. PubMed ID: 34237284
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antibody evasion by the P.1 strain of SARS-CoV-2.
    Dejnirattisai W; Zhou D; Supasa P; Liu C; Mentzer AJ; Ginn HM; Zhao Y; Duyvesteyn HME; Tuekprakhon A; Nutalai R; Wang B; López-Camacho C; Slon-Campos J; Walter TS; Skelly D; Costa Clemens SA; Naveca FG; Nascimento V; Nascimento F; Fernandes da Costa C; Resende PC; Pauvolid-Correa A; Siqueira MM; Dold C; Levin R; Dong T; Pollard AJ; Knight JC; Crook D; Lambe T; Clutterbuck E; Bibi S; Flaxman A; Bittaye M; Belij-Rammerstorfer S; Gilbert SC; Carroll MW; Klenerman P; Barnes E; Dunachie SJ; Paterson NG; Williams MA; Hall DR; Hulswit RJG; Bowden TA; Fry EE; Mongkolsapaya J; Ren J; Stuart DI; Screaton GR
    Cell; 2021 May; 184(11):2939-2954.e9. PubMed ID: 33852911
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The alpha/B.1.1.7 SARS-CoV-2 variant exhibits significantly higher affinity for ACE-2 and requires lower inoculation doses to cause disease in K18-hACE2 mice.
    Bayarri-Olmos R; Johnsen LB; Idorn M; Reinert LS; Rosbjerg A; Vang S; Hansen CB; Helgstrand C; Bjelke JR; Bak-Thomsen T; Paludan SR; Garred P; Skjoedt MO
    Elife; 2021 Nov; 10():. PubMed ID: 34821555
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization.
    Liu Z; VanBlargan LA; Bloyet LM; Rothlauf PW; Chen RE; Stumpf S; Zhao H; Errico JM; Theel ES; Liebeskind MJ; Alford B; Buchser WJ; Ellebedy AH; Fremont DH; Diamond MS; Whelan SPJ
    Cell Host Microbe; 2021 Mar; 29(3):477-488.e4. PubMed ID: 33535027
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mapping cross-variant neutralizing sites on the SARS-CoV-2 spike protein.
    Xu S; Wang Y; Wang Y; Zhang C; Hong Q; Gu C; Xu R; Wang T; Yang Y; Zang J; Zhou Y; Li Z; Liu Q; Zhou B; Bai L; Zhu Y; Deng Q; Wang H; Lavillette D; Wong G; Xie Y; Cong Y; Huang Z
    Emerg Microbes Infect; 2022 Dec; 11(1):351-367. PubMed ID: 34964428
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Limited Variation between SARS-CoV-2-Infected Individuals in Domain Specificity and Relative Potency of the Antibody Response against the Spike Glycoprotein.
    Van Ert HA; Bohan DW; Rogers K; Fili M; Rojas Chávez RA; Qing E; Han C; Dempewolf S; Hu G; Schwery N; Sevcik K; Ruggio N; Boyt D; Pentella MA; Gallagher T; Jackson JB; Merrill AE; Knudson CM; Brown GD; Maury W; Haim H
    Microbiol Spectr; 2022 Feb; 10(1):e0267621. PubMed ID: 35080430
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Emergency SARS-CoV-2 Variants of Concern: Novel Multiplex Real-Time RT-PCR Assay for Rapid Detection and Surveillance.
    Chung HY; Jian MJ; Chang CK; Lin JC; Yeh KM; Chen CW; Hsieh SS; Hung KS; Tang SH; Perng CL; Chang FY; Wang CH; Shang HS
    Microbiol Spectr; 2022 Feb; 10(1):e0251321. PubMed ID: 35196812
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.